173 related articles for article (PubMed ID: 8410185)
1. Dopamine transporter expression confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium.
Pifl C; Giros B; Caron MG
J Neurosci; 1993 Oct; 13(10):4246-53. PubMed ID: 8410185
[TBL] [Abstract][Full Text] [Related]
2. Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter.
Pifl C; Hornykiewicz O; Giros B; Caron MG
J Pharmacol Exp Ther; 1996 Jun; 277(3):1437-43. PubMed ID: 8667208
[TBL] [Abstract][Full Text] [Related]
3. Parkinsonism-inducing neurotoxin MPP+: uptake and toxicity in nonneuronal COS cells expressing dopamine transporter cDNA.
Kitayama S; Shimada S; Uhl GR
Ann Neurol; 1992 Jul; 32(1):109-11. PubMed ID: 1642464
[TBL] [Abstract][Full Text] [Related]
4. Inhibition by dizocilpine (MK-801) of striatal dopamine release induced by MPTP and MPP+: possible action at the dopamine transporter.
Clarke PB; Reuben M
Br J Pharmacol; 1995 Jan; 114(2):315-22. PubMed ID: 7881731
[TBL] [Abstract][Full Text] [Related]
5. MPP+ toxicity and plasma membrane dopamine transporter: study using cell lines expressing the wild-type and mutant rat dopamine transporters.
Kitayama S; Mitsuhata C; Davis S; Wang JB; Sato T; Morita K; Uhl GR; Dohi T
Biochim Biophys Acta; 1998 Sep; 1404(3):305-13. PubMed ID: 9739158
[TBL] [Abstract][Full Text] [Related]
6. A new in vitro approach for investigating the MPTP effect on DA uptake.
Barc S; Page G; Fauconneau B; Barrier L; Huguet F
Neurochem Int; 2001 Mar; 38(3):243-8. PubMed ID: 11099783
[TBL] [Abstract][Full Text] [Related]
7. Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake.
Storch A; Hwang YI; Gearhart DA; Beach JW; Neafsey EJ; Collins MA; Schwarz J
J Neurochem; 2004 May; 89(3):685-94. PubMed ID: 15086525
[TBL] [Abstract][Full Text] [Related]
8. Cocaine inhibits the release of MPP+ but not dopamine through the rat dopamine transporter.
Kitayama S; Morita K; Dohi T
Eur J Pharmacol; 1996 Aug; 309(1):107-9. PubMed ID: 8864700
[TBL] [Abstract][Full Text] [Related]
9. Species differences in functions of dopamine transporter: paucity of MPP+ uptake and cocaine binding in bovine dopamine transporter.
Lee SH; Rhee J; Koh JK; Lee YS
Neurosci Lett; 1996 Aug; 214(2-3):199-201. PubMed ID: 8878118
[TBL] [Abstract][Full Text] [Related]
10. Dopamine transporter mutants selectively enhance MPP+ transport.
Kitayama S; Wang JB; Uhl GR
Synapse; 1993 Sep; 15(1):58-62. PubMed ID: 8310426
[TBL] [Abstract][Full Text] [Related]
11. Structural significance of azaheterocyclic amines related to Parkinson's disease for dopamine transporter.
Matsubara K; Senda T; Uezono T; Fukushima S; Ohta S; Igarashi K; Naoi M; Yamashita Y; Ohtaki K; Hayase N; Akutsu S; Kimura K
Eur J Pharmacol; 1998 May; 348(1):77-84. PubMed ID: 9650834
[TBL] [Abstract][Full Text] [Related]
12. Dopamine transporter function assessed by antisense knockdown in the rat: protection from dopamine neurotoxicity.
Van Kampen JM; McGeer EG; Stoessl AJ
Synapse; 2000 Sep; 37(3):171-8. PubMed ID: 10881039
[TBL] [Abstract][Full Text] [Related]
13. [3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux.
Johnson RA; Eshleman AJ; Meyers T; Neve KA; Janowsky A
Synapse; 1998 Sep; 30(1):97-106. PubMed ID: 9704886
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells.
Fang J; Zuo D; Yu PH
Psychopharmacology (Berl); 1995 Oct; 121(3):373-8. PubMed ID: 8584620
[TBL] [Abstract][Full Text] [Related]
15. Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells.
Stephans SE; Miller GW; Levey AI; Greenamyre JT
Neurotoxicology; 2002 Oct; 23(4-5):569-80. PubMed ID: 12428729
[TBL] [Abstract][Full Text] [Related]
16. In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium.
Staal RG; Hogan KA; Liang CL; German DC; Sonsalla PK
J Pharmacol Exp Ther; 2000 May; 293(2):329-35. PubMed ID: 10772999
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine-533 of rat dopamine transporter: involvement in interactions with 1-methyl-4-phenylpyridinium and cocaine.
Mitsuhata C; Kitayama S; Morita K; Vandenbergh D; Uhl GR; Dohi T
Brain Res Mol Brain Res; 1998 May; 56(1-2):84-8. PubMed ID: 9602072
[TBL] [Abstract][Full Text] [Related]
18. Implication of dopamine transporter system on 1-methyl-4-phenylpyridinium and rotenone effect in striatal synaptosomes.
Bougria M; Vitorica J; Cano J; Machado A
Eur J Pharmacol; 1995 Nov; 291(3):407-15. PubMed ID: 8719427
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of MPP(+) incorporation into cerebellar granule cells.
González-Polo RA; Mora A; Clemente N; Sabio G; Centeno F; Soler G; Fuentes JM
Brain Res Bull; 2001 Sep; 56(2):119-23. PubMed ID: 11704348
[TBL] [Abstract][Full Text] [Related]
20. Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium.
Buck KJ; Amara SG
Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12584-8. PubMed ID: 7809082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
